WO2001081348A1 - Utilisation de 5-thio-, sulfinyl- et sulfonylpyrazolo[3,4-b]-pyridines comme inhibiteurs de la kinase dependant de la cycline - Google Patents
Utilisation de 5-thio-, sulfinyl- et sulfonylpyrazolo[3,4-b]-pyridines comme inhibiteurs de la kinase dependant de la cycline Download PDFInfo
- Publication number
- WO2001081348A1 WO2001081348A1 PCT/US2001/012327 US0112327W WO0181348A1 WO 2001081348 A1 WO2001081348 A1 WO 2001081348A1 US 0112327 W US0112327 W US 0112327W WO 0181348 A1 WO0181348 A1 WO 0181348A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- administering
- need
- inhibiting
- mammalian specie
- Prior art date
Links
- 0 COc1ccc(C[n]2nc(*)cc2N)cc1 Chemical compound COc1ccc(C[n]2nc(*)cc2N)cc1 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to inhibitors of cyclin dependent kinase and their use in the treatment of proliferative diseases.
- CDKs cyclin dependent kinases
- CDKs are serine/threonine protein kinases that are the driving force behind the cell cycle and cell proliferation.
- the active CDK enzyme is a multi-subunit complex composed of at least one catalytic (CDK) subunit and one regulatory (cyclin) subunit. See, Brooks and La Thangue, DDT, 4, 455-464 (1999). It has been found that inhibitors of CDK activity are effective for the treatment of proliferative diseases (e.g. , cancer). See, Webster and Kimball, Emerging Drugs, 5, 45-59 (2000).
- the present invention is directed to the use of compounds of formula
- Ri is hydrogen, aryl or lower alkyl
- R 2 and R are each independently alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl;
- R 3 is hydrogen or lower alkyl; and n is an integer of 0, 1 or 2.
- the compounds of formula I are protein kinase inhibitors and are useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of neurodegenerative diseases such Alzheimer's disease, cardiovascular diseases, viral diseases and fungal diseases.
- the present invention provides for a method of using compounds of formula I as inhibitors of cyclin dependent kinases, which are active in the treatment of proliferative diseases, such as for example, but not limited to, cancer, Alzheimer's disease, arthritis, inflammation, and cardiovascular disease.
- the present invention also contemplates pharmaceutical compositions employing such compounds.
- Carboxylate anion refers to a negatively charged group -COO " .
- alkyl or “alk” refers to a monovalent alkane (hydrocarbon) derived radical containing from 1 to 12 carbon atoms unless otherwise defined.
- lower alkyl refers to an alkyl group of 1 to 6 carbon atoms.
- An alkyl group is an optionally substituted straight, branched or cyclic saturated hydrocarbon group. When substituted, alkyl groups may be substituted with up to four substituent groups, R as defined, at any available point of attachment. When the alkyl group is said to be substituted with an alkyl group, this is used interchangeably with "branched alkyl group”.
- Exemplary unsubstituted such groups include methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4- dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, and the like.
- Alkyl groups as defined may also comprise one or more carbon to carbon double bonds or one or more carbon to carbon triple bonds.
- alkenyl refers to a hydrocarbon radical straight, branched or cyclic containing from 2 to 12 carbon atoms and at least one carbon to carbon double bond.
- alkynyl refers to a hydrocarbon radical straight, branched or cyclic containing from 2 to 12 carbon atoms and at least one carbon to carbon triple bond.
- Cycloalkyl is a type of alkyl containing from 3 to 15 carbon atoms, without alternating or resonating double bonds between carbon atoms. It may contain from 1 to 4 rings. Exemplary unsubstituted such groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc. Exemplary substituents include one or more of the following groups: halogen, alkyl, alkoxy, alkyl, hydroxy, amino, nitro, cyano, thiol and/or alkylthio.
- alkoxy or "alkylthio”, as used herein, denote an alkyl group as described above bonded through an oxygen linkage (-O-) or a sulfur linkage (-S-), respectively.
- alkyloxycarbonyl denotes an alkoxy group bonded through a carbonyl group.
- An alkoxycarbonyl radical is represented by the formula -C(O)OR, where the R group is a straight or branched C]. 6 alkyl group.
- alkyl carbonyl refers to an alkyl group bonded through a carbonyl group.
- alkylcarbonyloxy denotes an alkylcarbonyl group which is bonded through an oxygen linkage.
- arylalkyl denotes an aromatic ring bonded through an alkyl group as described above.
- aryl refers to monocyclic or bicyclic aromatic rings, e.g., phenyl, substituted phenyl and the like, as well as groups which are fused, e.g., napthyl, phenanthrenyl and the like.
- An aryl group thus contains at least one ring having at least 6 atoms, with up to five such rings being present, containing up to 22 atoms therein, with alternating (resonating) double bonds between adjacent carbon atoms or suitable heteroatoms.
- heteroaryl refers to a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to 10 atoms, containing at least one heteroatom, O, S, or N, in which a carbon or nitrogen atom is the point of attachment, and in which one or two additional carbon atoms is optionally replaced by a heteroatom selected from O or S, and in which from 1 to 3 additional carbon atoms are optionally replaced by nitrogen heteroatoms, said heteroaryl group being optionally substituted as described herein. Additional nitrogen atoms may be present together with the first nitrogen and oxygen or sulfur.
- heteroaryl groups include the following: thienyl, furyl, pyrrolyl, pyridinyl, imidazolyl, pyrrolidinyl, piperidinyl, thiazolyl, oxazolyl, triazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyrazinyl, pyridazinyl, pyrimidinal, triazinylazepinyl, indolyl, isoindolyl, quinolinyl, isoquinolinyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, benzoxadiazolyl, benzofurazanyl and tetrahydropyranyl.
- heteroarylalkyl denotes a heteroaryl ring bonded through an alkyl group as described hereinabove.
- heteroarylium refers to heteroaryl groups bearing a quaternary nitrogen atom and thus a positive charge.
- heterocycloalkyl refers to a cycloalkyl group (nonaromatic) in which one of the carbon atoms in the ring is replaced by a heteroatom selected from O, S or N, and in which up to three additional carbon atoms may be replaced by said heteroatoms.
- the sulfur may be oxidated to the sulfone (-SO 2 -) or sulfoxide (-SO-) and the nitrogen may be quaternary.
- quaternary nitrogen refers to a tetravalent positively charged nitrogen atom including, e.g., the positively charged nitrogen in a tetraalkylammonium group (e.g., tetramethylammonium, N-methylpyridinium), the positively charged nitrogen in protonated ammonium species (e.g., trimethylhydroammonium, N-hydropyridinium), the positively charged nitrogen in amine N-oxides (e.g. N-methyl-morpholine-N-oxide, pyridine-N-oxide), and the positively charged nitrogen in an N-amino-ammonium group (e.g., N-aminopyridinium) .
- a tetraalkylammonium group e.g., tetramethylammonium, N-methylpyridinium
- protonated ammonium species e.g., trimethylhydroammonium, N-hydropyridinium
- heteroatom means O, S, P or N, selected on an independent basis.
- halogen or halo refers to chlorine, bromine, fluorine or iodine.
- PMB para-methoxy benzyl
- protecting groups for the compounds of the present invention will be recognized from the present application taking into account the level of skill in the art, and with reference to standard textbooks, such as Greene, T. W. et al., Protective Groups in Organic Synthesis, Wiley, N.Y. (1991).
- salts of the compounds according to the invention with inorganic or organic acids are hydrochloride, hydrobromide, sulfate, phosphate. Salts which are unsuitable for pharmaceutical uses but which can be employed, for example, for the isolation or purification of free compounds I or their pharmaceutically acceptable salts, are also included.
- All stereoisomers of the compounds of the instant invention are contemplated, either in admixture or in pure or substantially pure form.
- the definition of the compounds according to the invention embraces all possible stereoisomers and their mixtures. It very particularly embraces the racemic forms and the isolated optical isomers having the specified activity.
- the racemic forms can be resolved by physical methods, such as, for example, fractional crystallization, separation or crystallization of diastereomeric derivatives or separation by chiral column chromatography.
- the individual optical isomers can be obtained from the racemates by conventional methods, such as, for example, salt formation with an optically active acid followed by crystallization.
- prodrug forms of the compounds of formula I includes prodrug forms of the compounds of formula I.
- Various forms of prodrugs are well known in the art. Examples of such prodrug derivatives are provided in the following references:
- solvates e.g., hydrates
- Methods of solvation are generally known in the art. Accordingly, the compounds of the instant invention may be in the free or hydrate form, and may be obtained by methods exemplified by the following schemes.
- the starting compound of formula II, where Ri is hydrogen is prepared by reacting acrylonitrile with hydrazine hydrate in a solvent such as THF, followed by addition of p-methoxybenzaldehyde. The compound which results from this reaction is then reacted with a mixture of sodium n-butoxide in n-butanol followed by HCl to provide the key early intermediate of compound II.
- the formula VII compound is reacted with bromine in the presence of a solvent such as ethanol, preferably at a temperature of about 0°C, to obtain a compound of formula VIII
- the formula XI compound is reacted with an organolithium reagent such as n-butyllithium in a solvent such as tetrahydrofuran, ether and the like at a temperature from about -90° to -20°C followed by treatment with a compound of formula XII
- an acid such as trifluoroacetic acid (TFA)
- TFA trifluoroacetic acid
- n 1 or 2
- an oxidizing agent such as m-chloroperoxybenzoic acid (mCPBA) and the like in the presence of a solvent such as dichloromethane.
- mCPBA m-chloroperoxybenzoic acid
- a solvent such as dichloromethane.
- one equivalent of the oxidizing agent is used to obtain compounds of formula I wherein n is 1, and two or more equivalents of the oxidizing agent are used to obtain compounds of formula I wherein n is 2.
- Intermediates of this invention may also be prepared by processes disclosed in U.S. Patent Nos. 3,828,057, 3,966,746, 3,979,399, and 3,985,757 which are inco ⁇ orated by reference herein. More specifically, intermediates of formula II may be prepared by procedures described in Hoehn, H., Z. Chem. 10, pp. 386-388 (1970). Compounds of formulas II and III are commercially available or may be prepared by methods known to one of ordinary skill in the art.
- R 2 is aryl or heteroaryl; R is alkyl, cycloalkyl or cycloalkylalkyl; and n is an integer of 0, 1 or 2. More preferred compounds of formula I are those wherein: R] and R 3 are hydrogen; R is phenyl, 4-bromo-2,6-difluorophenyl, 4-chloro-2,6- difluorophenyl, 2,4,6-trifluorophenyl or 4-methyl-2,6- difluorophenyl; R4 is lower alkyl; and n is 1.
- the compounds according to the invention have pharmacological properties; in particular, the compounds of formula I are inhibitors of protein kinases such as the cyclin dependent kinases (cdks), for example, cdc2 (cdkl), cdk2, and cdk4.
- cdks protein kinases
- cdc2 cyclin dependent kinases
- cdkl cyclin dependent kinases
- cdk2 cyclin dependent kinases
- cdk2 cyclin dependent kinases
- the compounds of formula I are useful in the treatment of a variety of cancers, including (but not limited to) the following:
- -carcinoma including that of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin;
- -hematopoietic tumors of lymphoid lineage including acute lymphocytic leukemia, B-cell lymphoma, and Burkett's lymphoma
- -hematopoietic tumors of myeloid lineage including acute and chronic myelogenous leukemias and promyelocytic leukemia
- tumors including melanoma, seminoma, teratocarcinoma, osteosarcoma, neuroblastoma and glioma.
- inhibitors could act as reversible cytostatic agents which may be useful in the treatment of any disease process which features abnormal cellular proliferation, e.g., neuro-fibromatosis, atherosclerosis, pulmonary fibrosis, arthritis, psoriasis, glomerulonephritis, restenosis following angioplasty or vascular surgery, hypertrophic scar formation, inflammatory bowel disease, transplantation rejection, angiogenesis, and endotoxic shock.
- Compounds of formula I may also be useful in the treatment of Alzheimer's disease, as suggested by the recent finding that cdk5 is involved in the phosphorylation of tau protein (J Biochem, 117, 741-749 (1995)).
- Compounds of formula I may also act as inhibitors of other protein kinases, e.g., protein kinase C, her2, rafl, MEKl, MAP kinase, EGF receptor, PDGF receptor, IGF receptor, PI3 kinase, weel kinase, Src, Abl, VEGF, and lck, and thus be effective in the treatment of diseases associated with other protein kinases.
- protein kinase C her2, rafl, MEKl
- MAP kinase e.g., EGF receptor, PDGF receptor, IGF receptor, PI3 kinase, weel kinase, Src, Abl, VEGF, and lck
- Compounds of formula I also induce or inhibit apoptosis, a physiological cell death process critical for normal development and homeostasis. Alterations of apoptotic pathways contribute to the pathogenesis of a variety of human diseases. Compounds of formula I, as modulators of apoptosis, will be useful in the treatment of a variety of human diseases with abberations in apoptosis including cancer (particularly, but not limited to, follicular lymphomas, carcinomas with p53 mutations, hormone dependent tumors of the breast, prostate and ovary, and precancerous lesions such as familial adenomatous polyposis), viral infections
- autoimmune diseases including, but not limited to, systemic lupus, erythematosus, immune mediated glomerulonephritis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, and autoimmune diabetes mellitus
- neurodegenerative disorders including, but not limited to, Alzheimer's disease, AIDS-related dementia, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, spinal muscular atrophy and cerebellar degeneration
- AIDS myelodysplastic syndromes, aplastic anemia, ischemic injury associated myocardial infarctions, stroke and reperfusion injury, arrhythmia, atherosclerosis, toxin-induced or alcohol induced liver diseases, hematological diseases (including, but not limited to, chronic anemia and aplastic anemia), degenerative diseases of the
- the compounds of this invention may also be useful in combination with known anti-cancer treatments such as radiation therapy or with cytostatic and cytotoxic agents, such as, for example, but not limited to, DNA interactive agents, such as cisplatin or doxorubicin; inhibitors of farnesyl protein transferase, such as those described in U.S. Patent No.
- cytostatic and cytotoxic agents such as, for example, but not limited to, DNA interactive agents, such as cisplatin or doxorubicin; inhibitors of farnesyl protein transferase, such as those described in U.S. Patent No.
- topoisomerase II inhibitors such as etoposide
- topoisomerase I inhibitors such as CPT-1 1 or topotecan
- tubulin stabilizing agents such as paclitaxel, docetaxel or the epothilones
- hormonal agents such as tamoxifen
- thymidilate synthase inhibitors such as 5-fluorouracil
- antimetabolites such as methoxtrexate
- antiangiogenic agents such as angiostatin or endostatin
- kinase inhibitors such as her2 specific antibodies.
- the formula I compounds of this invention may also be useful in combination with modulators of p53 transactivation.
- the formula I compounds may be used for treating chemotherapy-induced alopecia, chemotherapy-induced thrombocytopenia, chemotherapy-induced leukopenia or mucocitis.
- the formula I compound is preferably topically applied in the form of a medicament such as a gel, shampoo, aerosol, dust, cream, ointment, solution, dispersion or paste.
- such combination products employ the compounds of this invention within the dosage range described below and the other pharmaceutically active agent within its approved dosage range.
- the cdc2 inhibitor olomucine has been found to act synergistically with known cytotoxic agents in inducing apoptosis (J. Cell Sci., 108, 2897 (1995)).
- Compounds of formula I may be used sequentially with known anti-cancer or cytotoxic agents when a combination formulation is inappropriate.
- cdc2/cyclin Bl Kinase Assay cdc2/cyclin B 1 kinase activity was determined by monitoring the inco ⁇ oration of 32p into histone HI. The reaction consisted of 50 ng baculovirus expressed GST- cdc2, 75 ng baculovirus expressed GST-cyclin Bl, 1 ⁇ g histone HI (Boehringer
- kinase buffer 50 mM Tris, pH 8.0, 10 mM MgCl2, 1 mM EGTA, 0.5 mM DTT.
- TCA cold trichloroacetic acid
- the reaction was harvested onto GF/C unifilter plates (Packard) using a Packard Filtermate Universal harvester, and the filters were counted on a Packard TopCount 96-well liquid scintillation counter (Marshak, D.R., Vanderberg, M.T., Bae, Y.S., Yu, I.J., J. Cellular Biochemistry, 45, 391-400 (1991), inco ⁇ orated by reference herein).
- cdk2/cyclin E Kinase Assay cdk2/cyclin E Kinase Assay cdk2/cyclin E kinase activity was determined by monitoring the inco ⁇ oration of 2p into the retinoblastoma protein. The reaction consisted of 2.5 ng baculovirus expressed GST-cdk2/cyclin E, 500 ng bacterially produced GST-retinoblastoma protein (aa 776-928), 0.2 ⁇ Ci 32 P ⁇ -ATP and 25 ⁇ M ATP in kinase buffer (50 mM Hepes, pH 8.0, 10 mM MgCl2, 5 mM EGTA, 2 mM DTT).
- the reaction was incubated at 30 °C for 30 minutes and then stopped by the addition of cold trichloroacetic acid (TCA) to a final concentration of 15% and incubated on ice for 20 minutes.
- TCA cold trichloroacetic acid
- the reaction was harvested onto GF/C unifilter plates (Packard) using a Packard Filtermate Universal harvester, and the filters were counted on a Packard
- cdk4/cyclin Dl Kinase activity was determined by monitoring the inco ⁇ oration of 32 P in to the retinoblastoma protein.
- the reaction consisted of 165 ng baculovirus expressed as GST-cdk4, 282 ng bacterially expressed as S-tag cyclin Dl, 500 ng bacterially produced GST-retinoblastoma protein (aa 776-928), 0.2 ⁇ Ci 32 P ⁇ - ATP and 25 ⁇ M ATP in kinase buffer (50 mM Hepes, pH 8.0, 10 mM MgCl 2 , 5 mM EGTA, 2 mM DTT).
- the reaction was incubated at 30 °C for 1 hour and then stopped by the addition of cold trichloroacetic acid (TCA) to a final concentration of 15% and incubated on ice for 20 minutes.
- TCA cold trichloroacetic acid
- the reaction was harvested onto GF/C unifilter plates (Packard) using a Packard Filtermate Universal harvester, and the filters were counted on a Packard TopCount 96-well liquid scintillation counter (Coleman, K.G., Wautlet, B.S., Morissey, D, Mulheron, J.G., Sedman, S., Brinkley, P., Price, S., Webster, K.R. (1997) Identification of CDK4 Sequences involved in cyclin D, and pl6 binding. J. Biol. Chem. 272,30: 18869-18874, inco ⁇ orated by reference herein).
- compositions for use as described above including controlling cancer, inflammation and arthritis, which contain at least one compound of formula I as defined above or at least one of its pharmacologically acceptable acid addition salts, and the use of a compound of formula I as defined above for the preparation of a pharmaceutical having activity against proliferative diseases as described previously including against cancer, inflammation and/or arthritis.
- Part B compound as an amber glass.
- the oil was removed from a 660 mg (60% in oil, 16 mmol) portion of sodium hydride dispersion by three washes with hexane then covered with 30 mL of dry THF. The mixture was heated to 50° then, in two portions, a total of 2.3 mL (25 mmol) of anhydrous n-butanol was added. The reaction mixture was stirred until gas evolution ceased, -30 min, then cooled to room temperature. To the resulting solution was added 2.92 g (8.28 mmol) of Part D compound and stirred at 60°C for 2 hr then cooled to room temperature and concentrated in vacuo to give a solid. The solid was partitioned between 50 mL of water and 50 mL of EtOAc.
- Part G compound A solution of 60 mg (0.15 mmol) of Part F compound in 1 mL of trifluoroacetic acid was heated to 65°C for 2.5 hr then cooled to room temperature and concentrated in vacuo. An aqueous saturated sodium bicarbonate solution was added to the residue. The solid which formed was collected by filtration then recrystallized (EtOAc/hexane) to afford 28 mg (62%) of Part G compound.
- Example 2 To a solution of 28 mg (0.094 mmol) of Example 1, Part G compound in 25 mL of methylene chloride at room temperature was added 56 mg (tech 80%, 0.26 mmol) of m-chloroperoxybenzoic acid. The reaction mixture was stirred for 1 hr, aqueous sodium bicarbonate solution was added then after 2 hr the mixture was dried (sodium sulfate) and concentrated in vacuo to give the crude product. Crystallization (methylene chloride/hexane) of the crude material afforded 24 mg (78%) of the title compound as a white solid.
- MeOH/water/phosphoric acid (90: 10:0.2)) 18.1 min, 90% of total peak area at 220 nM.
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001578438A JP2004507455A (ja) | 2000-04-25 | 2001-04-13 | サイクリン依存性キナーゼ阻害剤としての、5−チオ−、スルフィニル−およびスルホニルピラゾロ[3,4−b]−ピリジンの用途 |
DE60108626T DE60108626T2 (de) | 2000-04-25 | 2001-04-13 | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer |
EP01927052A EP1278749B1 (fr) | 2000-04-25 | 2001-04-13 | Utilisation de 5-thio-, sulfinyl- et sulfonylpyrazolo 3,4-b]-pyridines comme inhibiteurs de la kinase dependant de la cycline |
AU2001253540A AU2001253540A1 (en) | 2000-04-25 | 2001-04-13 | Use of 5-thio-, sulfinyl- and sulfonylpyrazolo(3,4-b)-pyridines as cyclin dependent kinase inhibitors |
AT01927052T ATE287886T1 (de) | 2000-04-25 | 2001-04-13 | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer |
CA002407445A CA2407445A1 (fr) | 2000-04-25 | 2001-04-13 | Utilisation de 5-thio-, sulfinyl- et sulfonylpyrazolo¬3,4-b|-pyridines comme inhibiteurs de la kinase dependant de la cycline |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19947500P | 2000-04-25 | 2000-04-25 | |
US60/199,475 | 2000-04-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001081348A1 true WO2001081348A1 (fr) | 2001-11-01 |
Family
ID=22737659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/012327 WO2001081348A1 (fr) | 2000-04-25 | 2001-04-13 | Utilisation de 5-thio-, sulfinyl- et sulfonylpyrazolo[3,4-b]-pyridines comme inhibiteurs de la kinase dependant de la cycline |
Country Status (9)
Country | Link |
---|---|
US (1) | US6448264B2 (fr) |
EP (1) | EP1278749B1 (fr) |
JP (1) | JP2004507455A (fr) |
AT (1) | ATE287886T1 (fr) |
AU (1) | AU2001253540A1 (fr) |
CA (1) | CA2407445A1 (fr) |
DE (1) | DE60108626T2 (fr) |
ES (1) | ES2236217T3 (fr) |
WO (1) | WO2001081348A1 (fr) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2851247A1 (fr) * | 2003-02-19 | 2004-08-20 | Exonhit Therapeutics Sa | Methodes et compositions pour le traitement de pathologies degeneratives oculaires |
FR2856595A1 (fr) * | 2003-06-27 | 2004-12-31 | Exonhit Therapeutics Sa | Methodes et compositions pour le traitement de deficits cognitifs. |
WO2005002552A2 (fr) | 2003-07-03 | 2005-01-13 | Astex Therapeutics Limited | Composes pharmaceutiques |
WO2005012256A1 (fr) | 2003-07-22 | 2005-02-10 | Astex Therapeutics Limited | Composes 1h-pyrazole 3,4-disubstitues et leur utilisation en tant que kinases dependant des cyclines (cdk) et modulateurs de la glycogene synthase kinase-3 (gsk-3) |
WO2005068473A1 (fr) * | 2003-12-17 | 2005-07-28 | Sgx Pharmaceuticals, Inc. | Composes a fusion pyrazolo bicycliques utilises comme modulateurs de proteine kinases |
WO2006077424A1 (fr) | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Composes pharmaceutiques |
WO2006077428A1 (fr) | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Composes pharmaceutiques |
JP2006519205A (ja) * | 2003-02-27 | 2006-08-24 | ホタ・ウリアツチ・イーグリエガ・コンパーニア・ソシエダツド・アノニマ | ピラゾロピリジン誘導体 |
WO2007103308A2 (fr) | 2006-03-07 | 2007-09-13 | Array Biopharma Inc. | Dérivés hétérobicycliques de pyrazole et méthodes d'utilisation |
EP2395000A1 (fr) | 2004-12-30 | 2011-12-14 | Astex Therapeutics Limited | Composés de benzimidazole régulant l' activite de kinases CDK, GSK et aurora |
US9717719B2 (en) | 2006-09-08 | 2017-08-01 | Rhode Island Hospital | Treatment, prevention, and reversal of alcohol-induced liver disease |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1648455A4 (fr) * | 2003-07-23 | 2009-03-04 | Exelixis Inc | Modulateurs de la proteine alk (anaplastic lymphoma kinase) et leurs methodes d'utilisation |
FR2876584B1 (fr) * | 2004-10-15 | 2007-04-13 | Centre Nat Rech Scient Cnrse | Utilisation de la kenpaullone pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules |
CA2681828A1 (fr) * | 2007-03-28 | 2008-10-09 | Universidad De Barcelona | Produits cd6 pour le traitement de la sepsie |
EP3183239B1 (fr) * | 2014-08-22 | 2018-09-26 | Merck Patent GmbH | Indazoles |
MX2018006250A (es) | 2015-11-18 | 2018-09-05 | Genzyme Corp | Biomarcador de enfermedad poliquistica renal y usos del mismo. |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3903096A (en) * | 1974-03-29 | 1975-09-02 | Squibb & Sons Inc | New derivatives of sulfonyl-, sulfinyl- and sulfenyl-1H-pyrazolo {8 3,4-b{9 -pyridines |
WO1995034563A1 (fr) * | 1994-06-16 | 1995-12-21 | Pfizer Inc. | Pyrazolo et pyrrolopyridines |
WO1999030710A1 (fr) * | 1997-12-13 | 1999-06-24 | Bristol-Myers Squibb Company | UTILISATION DE PYRAZOLO[3,4-b]PYRIDINE EN TANT QU'INHIBITEURS DE KINASE DEPENDANT DE LA CYCLINE |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9911053D0 (en) | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
YU9602A (sh) | 1999-08-12 | 2004-11-25 | Pharmacia Italia S.P.A. | Derivati 3(5)-amino-pirazola, postupak za njihovu izradu i njihova upotreba kao antitumornih agenasa |
US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
-
2001
- 2001-04-13 AT AT01927052T patent/ATE287886T1/de not_active IP Right Cessation
- 2001-04-13 ES ES01927052T patent/ES2236217T3/es not_active Expired - Lifetime
- 2001-04-13 EP EP01927052A patent/EP1278749B1/fr not_active Expired - Lifetime
- 2001-04-13 AU AU2001253540A patent/AU2001253540A1/en not_active Abandoned
- 2001-04-13 JP JP2001578438A patent/JP2004507455A/ja active Pending
- 2001-04-13 DE DE60108626T patent/DE60108626T2/de not_active Expired - Fee Related
- 2001-04-13 CA CA002407445A patent/CA2407445A1/fr not_active Abandoned
- 2001-04-13 WO PCT/US2001/012327 patent/WO2001081348A1/fr active IP Right Grant
- 2001-04-24 US US09/841,668 patent/US6448264B2/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3903096A (en) * | 1974-03-29 | 1975-09-02 | Squibb & Sons Inc | New derivatives of sulfonyl-, sulfinyl- and sulfenyl-1H-pyrazolo {8 3,4-b{9 -pyridines |
WO1995034563A1 (fr) * | 1994-06-16 | 1995-12-21 | Pfizer Inc. | Pyrazolo et pyrrolopyridines |
WO1999030710A1 (fr) * | 1997-12-13 | 1999-06-24 | Bristol-Myers Squibb Company | UTILISATION DE PYRAZOLO[3,4-b]PYRIDINE EN TANT QU'INHIBITEURS DE KINASE DEPENDANT DE LA CYCLINE |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004073711A3 (fr) * | 2003-02-19 | 2005-04-14 | Exonhit Therapeutics Sa | Methodes impliquant la pde4, compositions et leur criblage pour le traitement de pathologies neurodegeneratives oculaires |
US7872015B2 (en) | 2003-02-19 | 2011-01-18 | Exonhit Therapeutics Sa | Methods involving PDE4, compositions, and the screening thereof, for the treatment of degenerative ocular pathologies |
FR2851247A1 (fr) * | 2003-02-19 | 2004-08-20 | Exonhit Therapeutics Sa | Methodes et compositions pour le traitement de pathologies degeneratives oculaires |
JP4814783B2 (ja) * | 2003-02-27 | 2011-11-16 | パラウ ファルマ、 ソシエダッド アノニマ | ピラゾロピリジン誘導体 |
JP2006519205A (ja) * | 2003-02-27 | 2006-08-24 | ホタ・ウリアツチ・イーグリエガ・コンパーニア・ソシエダツド・アノニマ | ピラゾロピリジン誘導体 |
JP2007520427A (ja) * | 2003-06-27 | 2007-07-26 | エグゾニ・テラピューティック・ソシエテ・アノニム | 認知障害の処置のためのピラゾロピリジンの使用 |
AU2004251466B2 (en) * | 2003-06-27 | 2010-01-07 | Exonhit Therapeutics Sa | Use of pyrazolopyridines for the treatment of cognitive deficits |
FR2856595A1 (fr) * | 2003-06-27 | 2004-12-31 | Exonhit Therapeutics Sa | Methodes et compositions pour le traitement de deficits cognitifs. |
WO2005000302A1 (fr) * | 2003-06-27 | 2005-01-06 | Exonhit Therapeutics Sa | Utilisation de pyrazolopyridines pour le traitement de deficits cognitifs |
WO2005002552A2 (fr) | 2003-07-03 | 2005-01-13 | Astex Therapeutics Limited | Composes pharmaceutiques |
EP2305250A1 (fr) | 2003-07-03 | 2011-04-06 | Astex Therapeutics Limited | Dérivés de la benzimidazole et leur utilisation en tant qu'inhibiteurs de proteine kinases |
WO2005012256A1 (fr) | 2003-07-22 | 2005-02-10 | Astex Therapeutics Limited | Composes 1h-pyrazole 3,4-disubstitues et leur utilisation en tant que kinases dependant des cyclines (cdk) et modulateurs de la glycogene synthase kinase-3 (gsk-3) |
EP2256106A1 (fr) | 2003-07-22 | 2010-12-01 | Astex Therapeutics Limited | Composes 1H-pyrazole 3,4-disubstitues et leur utilisation en tant que kinases dependant des cyclines (CDK) et modulateurs de la glycogene synthase kinase-3 (GSK-3) |
WO2005068473A1 (fr) * | 2003-12-17 | 2005-07-28 | Sgx Pharmaceuticals, Inc. | Composes a fusion pyrazolo bicycliques utilises comme modulateurs de proteine kinases |
JP2007520463A (ja) * | 2003-12-17 | 2007-07-26 | エスジーエックス ファーマシューティカルズ,インコーポレイティド | プロテインキナーゼモジュレーターとしての二環ピラゾロ−縮合化合物 |
US7473783B2 (en) | 2003-12-17 | 2009-01-06 | Sgx Pharmaceuticals, Inc. | Bicyclic pyrazolo protein kinase modulators |
JP4728965B2 (ja) * | 2003-12-17 | 2011-07-20 | エスジーエックス ファーマシューティカルズ、インコーポレイテッド | プロテインキナーゼモジュレーターとしての二環ピラゾロ−縮合化合物 |
EP2395000A1 (fr) | 2004-12-30 | 2011-12-14 | Astex Therapeutics Limited | Composés de benzimidazole régulant l' activite de kinases CDK, GSK et aurora |
WO2006077428A1 (fr) | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Composes pharmaceutiques |
WO2006077424A1 (fr) | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Composes pharmaceutiques |
WO2007103308A2 (fr) | 2006-03-07 | 2007-09-13 | Array Biopharma Inc. | Dérivés hétérobicycliques de pyrazole et méthodes d'utilisation |
US9717719B2 (en) | 2006-09-08 | 2017-08-01 | Rhode Island Hospital | Treatment, prevention, and reversal of alcohol-induced liver disease |
Also Published As
Publication number | Publication date |
---|---|
CA2407445A1 (fr) | 2001-11-01 |
AU2001253540A1 (en) | 2001-11-07 |
US6448264B2 (en) | 2002-09-10 |
JP2004507455A (ja) | 2004-03-11 |
US20020002178A1 (en) | 2002-01-03 |
EP1278749B1 (fr) | 2005-01-26 |
DE60108626D1 (de) | 2005-03-03 |
ES2236217T3 (es) | 2005-07-16 |
EP1278749A1 (fr) | 2003-01-29 |
ATE287886T1 (de) | 2005-02-15 |
DE60108626T2 (de) | 2005-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6107305A (en) | Use of pyrazolo [3,4-b] pyridine as cyclin dependent kinase inhibitors | |
US6515004B1 (en) | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases | |
EP1278749B1 (fr) | Utilisation de 5-thio-, sulfinyl- et sulfonylpyrazolo 3,4-b]-pyridines comme inhibiteurs de la kinase dependant de la cycline | |
EP1087951B9 (fr) | Aminothiazole a substituant carbone, inhibiteurs de kinases dependantes de cycline | |
ZA200204349B (en) | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases. | |
EP1240166B1 (fr) | Inhibiteurs contenant n-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibant des kinases dependantes des cyclines | |
US6610724B2 (en) | 3-Aminopyrazole inhibitors of cyclin dependent kinases | |
IL153591A (en) | History of N–] 5 -))) 5– Alkyl– 2 – Oxazolil (Thio (–2 – thiazolil [carboxamide and pharmaceutical preparations containing them) | |
ZA200300452B (en) | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 578438 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001253540 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2407445 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001927052 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001927052 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001927052 Country of ref document: EP |